WO2010126355A1 - Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque - Google Patents

Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque Download PDF

Info

Publication number
WO2010126355A1
WO2010126355A1 PCT/NL2009/050237 NL2009050237W WO2010126355A1 WO 2010126355 A1 WO2010126355 A1 WO 2010126355A1 NL 2009050237 W NL2009050237 W NL 2009050237W WO 2010126355 A1 WO2010126355 A1 WO 2010126355A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
mirna
heart failure
subject
solexa
Prior art date
Application number
PCT/NL2009/050237
Other languages
English (en)
Inventor
Esther Elisa Johanna Maria Creemers
Yigal-Martin Pinto
Anke Johanna Marina Tijsen
Original Assignee
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Medisch Centrum Bij De Universiteit Van Amsterdam filed Critical Academisch Medisch Centrum Bij De Universiteit Van Amsterdam
Priority to PCT/NL2009/050237 priority Critical patent/WO2010126355A1/fr
Priority to PCT/NL2010/050251 priority patent/WO2010126370A2/fr
Priority to US13/263,976 priority patent/US20120115929A1/en
Priority to JP2012508418A priority patent/JP5871791B2/ja
Priority to PL10769995T priority patent/PL2425016T3/pl
Priority to AU2010242163A priority patent/AU2010242163B2/en
Priority to EP10769995.1A priority patent/EP2425016B1/fr
Priority to CA2758928A priority patent/CA2758928A1/fr
Priority to CN201080018687.1A priority patent/CN102421917B/zh
Priority to CN201410314395.2A priority patent/CN104087662A/zh
Priority to KR1020117028404A priority patent/KR101758667B1/ko
Priority to EP15158646.8A priority patent/EP2907879A3/fr
Priority to SG2011079399A priority patent/SG175821A1/en
Priority to DK10769995.1T priority patent/DK2425016T3/en
Publication of WO2010126355A1 publication Critical patent/WO2010126355A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Definitions

  • the invention relates to the fields of biology and medicine. More in particular, the present invention relates to miRNAs for use in diagnosis and therapy of heart failure.
  • MicroRNAs are small RNA molecules encoded in the genomes of plants and animals. They are present within introns of protein-coding genes, in polycistronic transcripts encoding multiple miRNAs and in individual miRNA genes. These highly conserved RNAs with a length of approximately 21-23 nucleotides usually regulate the expression of genes by binding to the 3'-untranslated regions (3'-UTRs) of specific mRNAs. Each miRNA is thought to regulate multiple genes, and since hundreds of miRNA genes are predicted to be present in higher eukaryotes the potential regulatory circuitry afforded by miRNA is enormous.
  • miRNAs act as key regulators of processes as diverse as early development, cell proliferation and cell death, apoptosis and fat metabolism, and cell differentiation. There is speculation that in higher eukaryotes, the role of miRNAs in regulating gene expression could be as important as that of transcription factors. Over 540 human miRNAs have been validated to date; however, computer models suggest there may be thousands more. It is believed that up to 30% of human genes are regulated by miRNAs.
  • RNA polymerase II The genes that encode miRNAs are transcribed from DNA by RNA polymerase II but not translated into protein.
  • the primary transcripts which generally have a length of several kilobases, are called pri-miRNAs.
  • Pri-miRNAs are processed in the cell nucleus to shorter, 70-100 nucleotide stem-loop structures known as pre-miRNAs. This processing is performed in animals by the RNase III endonuclease Drosha.
  • Pre-miRNAs are subsequently transported into the cytoplasm, where they are processed to double- stranded miRNAs with a length of 21-23 nucleotides by a second RNase III endonuclease, DICER.
  • RISC RNA-induced silencing complex
  • miRNAs have been linked to cancer and heart disease. Expression analysis studies reveal perturbed miRNA expression in tumors compared to normal tissues. MicroRNAs are deregulated in breast, lung, and colon cancer, and upregulated in Burkitt's and other human B-cell lymphomas. As a consequence, human miRNAs are likely to be highly useful as biomarkers, especially for future cancer diagnostics, and are rapidly emerging as attractive targets for disease intervention. In addition to their link with cancer, microRNAs play an important role in the control of diverse aspects of cardiac function and dysfunction, including myocyte growth, integrity of the ventricular wall, contractility, gene expression, and maintenance of cardiac rhythm. The misexpression of miRNAs has been shown to be necessary and sufficient for multiple forms of heart disease.
  • miRNAs are also present in blood. Several miRNAs could be detected at relatively high levels in serum, plasma, platelets, erythrocytes, as well as the nucleated blood cells. Aberrant expression profiles of miRNAs have been described in blood of subjects with sickle cell anaemia or in prostate cancer.
  • BNP brain natriuretic peptide
  • miRNA blood profiles are altered in hearth disease. Without whishing to be bound by any theory, it is believed that cells, including cardiac myocytes, excrete these miRNAs via exosomes into the blood and that the excretion pattern is changed in disease. Thus, the present inventors have shown that miRNA profiling in blood can be used as a novel tool for diagnostic or biomarker approaches in heart failure.
  • the present invention provides in a first aspect a method for treating or preventing heart failure in a subject the method comprising the step of: - decreasing within said subject the expression, amount, and/or activity of at least one miRNA; or
  • the present invention provides a method for treating or preventing heart failure in a subject the method comprising the step of:
  • the expression, amount, and/or activity of the mRNA target of at least one miRNA wherein said at least one miRNA is selected from the group consisting of miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221.
  • said step of increasing the expression, amount and/or activity or the interaction of said miRNA comprises administering to said subject said miRNA as functional miRNA, as precursor microRNA (pre-miRNA), or as microRNA primary transcript (pri- miRNA).
  • the present invention provides a miRNA selected from the group consisting of miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221, or a precursor microRNA (pre- miRNA) or a microRNA primary transcript thereof, for use as a medicament, preferably for use in the treatment or prevention of heart failure.
  • a miRNA selected from the group consisting of miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221, or a precursor microRNA (pre- miRNA) or a microRNA primary transcript thereof, for use as a medicament, preferably for use in the treatment or prevention of heart failure.
  • the present invention provides a compound, preferably a nucleic acid, capable of specifically binding to and thereby inhibiting the activity and/or function of at least one miRNA selected from the group consisting of miR-191*, miR-15b, miR-1228*, miR-181a, miR- 18a*, miR-107, miR-299-3p, miR-342-3p, and miR-652, and precursor microRNAs (pre-miRNA) or microRNA primary transcripts thereof for use as a medicament, preferably for use in the treatment or prevention of heart failure.
  • the term "function" herein refers in particular to the capacity of the said miRNA to inhibit translation of the target mRNA.
  • the nucleic acid is therefore preferably capable of inhibiting the hybridization in a sequence- specific manner between the miRNA and its mRNA target.
  • the term "specifically binding to" in the context of a nucleic acid as defined herein refers in particular to a nucleic acid that is capable of hybridizing under stringent conditions to the said miRNA.
  • the said nucleic acid has a sequence that is the complement of the sequence of the miRNA as provided in Figure 3.
  • the present invention provides a vector comprising a nucleic acid sequence encoding a nucleic acid capable of specifically binding to and thereby inhibiting the activity and/or function of at least one miRNA selected from the group consisting of miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR- 342-3p, and miR-652, and precursor microRNAs (pre-miRNA) or microRNA primary transcripts thereof or a miRNA selected from the group consisting of miR-191, miR-302d, miR-30e, miR-744, solexa-2952- 306, and solexa-3927-221, and precursor microRNAs (pre-miRNA) and microRNA primary transcripts thereof, and capable of expressing said nucleic acid or (pre or pri) miRNA, for use as a medicament, preferably for use in the treatment or prevention of heart failure.
  • miRNA miRNA selected from the group consisting of miR-19
  • the present invention provides a cell comprising a vector according to the invention as described above, for use as a medicament, preferably for use in the treatment or prevention of heart failure.
  • a pharmaceutical composition for treating or preventing heart failure in a subject comprising:
  • the present invention provides a method for diagnosing a subject as suffering from heart failure or being at risk of developing heart failure, the method comprising: a) determining the level of a genetic marker in a sample obtained from said subject, wherein said genetic marker is a miRNA selected from the group consisting of miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR-342-3p, miR-652, miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221, and precursor microRNAs (pre-miRNA) or microRNA primary transcripts thereof; b) diagnosing whether the subject suffers from heart failure or is at risk of developing heart failure based on the level of a genetic marker determined in step a).
  • a genetic marker is a miRNA selected from the group consisting of miR-191*, miR-15b, miR-1228*, miR
  • said step b) takes into account that said subject suffers from heart failure or is at risk of developing heart failure when:
  • miR-191*, miR-15b, miR- 1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR-342-3p and/or miR-652, or precursor microRNAs (pre-miRNA) or microRNA primary transcripts thereof, is upregulated relative to a control subject not suffering from or not being at risk of developing heart failure; and/or
  • miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and/or solexa-3927-221, or precursor microRNAs (pre-miRNA) or microRNA primary transcripts thereof, is downregulated relative to a control subject not suffering from or not being at risk of developing heart failure.
  • the present invention provides a kit of parts for diagnosing a subject as suffering from heart failure or being at risk of developing heart failure comprising:
  • At least one compound capable of specifically binding to at least one miRNA selected from the group consisting of miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR-342-3p, miR-652, miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221, and precursor microRNAs (pre-miRNA) or microRNA primary transcripts thereof; and
  • the present invention provides a ethod for determining whether a candidate compound is capable of treating or preventing heart failure in a human subject, the method comprising:
  • a human tissue cell preferably a cardiac tissue cell
  • said candidate compound is capable of modulating the expression, amount and/or activity of any one of miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR- 342-3p, miR-652, miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221 in said tissue cell.
  • said compound affects the expression of all miRNAs into a direction no longer associated with (a risk of) heart failure.
  • the method comprises:
  • tissue cell preferably a human tissue cell, more preferably a cardiac tissue cell
  • candidate compound is capable of decreasing the expression, amount and/or activity of miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR-342-3p, miR-652, and/or increasing the expression of miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, or solexa-3927-221 in said tissue cell.
  • the aspect of the invention pertaining to the screening of candidate therapeutic compounds may also be performed in a model system, for instance an animal model, which exhibits specific miRNA expression patterns associated with (an increased risk of) heart failure as indicated herein.
  • a further aspect of the invention is a (animal, including human) model system that exhibits a miRNA expression profile associated with (an increased risk of) heart failure as indicated herein.
  • Such model systems may be used in methods for screening for candidate therapeutic agents comprising the step of exposing (cells of) said model system to or administering to said model system a candidate compound and determining whether said candidate compound is capable of inducing a change in said miRNA expression profile that is no longer associated with (an increased risk of) heart failure, in particular capable of increasing the expression, amount and/or activity of miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, miR-342-3p, miR-652, miR- 191, miR-302d, miR-30e, miR-744, solexa-2952-306, or solexa-3927-221 in (cells of) said model system, and/or lowering the expression, amount and/or activity of
  • Figure 1 shows miRNAs enriched in plasma of heart failure (HF) patients.
  • Plasma samples 1) healthy person 1; 2) healthy person 2; 4) HF patient 1; 5) HF patient 2; 6) HF patient 3.
  • Figure 2 shows miRNAs down-regulated in plasma of heart failure patients. Plasma samples: 1) healthy person 1; 2) healthy person 2; 4) HF patient 1; 5) HF patient 2; 6) HF patient 3.
  • Figure 3 shows the sequences of the miRNAs as discussed herein as well as the genes encoding their target mRNA.
  • heart failure refers to the pathophysiologic state in which the heart, via an abnormality of cardiac function (detectable or not), fails to pump blood at a rate commensurate with the requirements of the metabolizing tissues and/or pumps only from an abnormally elevated diastolic filling pressure.
  • Heart failure may be caused by myocardial failure but may also occur in the presence of near- normal cardiac function under conditions of high demand. Heart failure always causes circulatory failure, but the converse is not necessarily the case because various noncardiac conditions (eg, hypovolemic shock, septic shock) can produce circulatory failure in the presence of normal, modestly impaired, or even supranormal cardiac function.
  • noncardiac conditions eg, hypovolemic shock, septic shock
  • nucleic acid includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single-or double- stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single- stranded nucleic acids in a manner similar to naturally occurring nucleotides (e. g., peptide nucleic acids).
  • isolated refers to material, such as a cell, which is substantially or essentially free from components that normally accompany or interact with it as found in its naturally occurring environment.
  • An isolated cell may be a cell culture obtained by culturing a cell that has been separated from a tissue in which is normally resides and that is no longer integrated in the tissue of the organism from which it is derived.
  • Nucleotides are referred to by their commonly accepted single- letter codes following IUPAC nomenclature: A (Adenine), C (Cytosine), T (Thymine), G (Guanine), U (Uracil), W (A or T), R (A or G), K (G or T), Y (C or T), S (C or G), M (A or C), B (C, G or T), H (A, C, or T), D (A, G, or T), V (A, C, or G), N (A, C, G, or T).
  • a “coding” or “encoding” sequence is the part of a gene that codes for the amino acid sequence of a protein, or for a functional RNA such as a tRNA or rRNA.
  • gene refers to a DNA sequence including but not limited to a DNA sequence that can be transcribed into mRNA which can be translated into polypeptide chains, transcribed into rRNA or tRNA or serve as recognition sites for enzymes and other proteins involved in DNA replication, transcription and regulation.
  • the term refers to any DNA sequence comprising several operably linked DNA fragments such as a promoter region, a 5' untranslated region (the 5' UTR), a coding region (which may or may not code for a protein), and an untranslated 3' region (3' UTR) comprising a polyadenylation site.
  • the 5'UTR, the coding region and the 3'UTR are transcribed into an RNA of which, in the case of a protein encoding gene, the coding region is translated into a protein.
  • the gene usually comprises introns and exons
  • a gene may include additional DNA fragments such as, for example, introns.
  • sample is used in its broadest sense as containing nucleic acids.
  • a sample may comprise a bodily fluid such as blood; the soluble fraction of a cell preparation, or an aliquot of media in which cells were grown; a chromosome, an organelle, or membrane isolated or extracted from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue; a tissue print; a fingerprint, buccal cells, skin, or hair; and the like.
  • the present invention relates to the diagnostic prognostic and therapeutic use of miRNAs indicated herein as hsa-mir-191*, has-miR-15b, hsa-miR-1228*, hsa-miR-181a, hsa-miR-18a*, hsa-miR-107, hsa-miR-299-3p, hsa-miR-342-3p, hsa-miR-652, hsa-miR-191, has-miR-302d, hsa-miR-30e, hsa-miR-744, solexa-2952-306, solexa-3927-221.
  • MiRNAs counteract the expression of a specific gene product by annealing to the niRNA encoded by the gene that encodes the proteinaceous gene product.
  • miRNA has the ability to translationally repress a target niRNA thereby regulating a target niRNA functionally.
  • Expression of the gene products encoded by these mRNAs in a cell is thus influenced by influencing the expression, amount and/or activity of at least one miRNA selected from the group consisting of hsa-mir-191*, hsa-miR-15b, hsa-miR-1228*, hsa-miR-181a, hsa-miR-18a*, hsa-miR-107, hsa-miR-299-3p, hsa-miR-342-3p, hsa-miR-652, hsa-miR-191, has-miR-302d, hsa-miR-30e, hsa-miR-744, solexa-2952-306, and solexa-3927-221, or a functional part or derivative thereof, within said cell, and/or by influencing interaction of the target mRNA with at least one miRNA selected from the group consisting of hsa-mir-19
  • miRNAs as mentioned herein are capable of counteracting expression of specific gene products.
  • miRNA encompasses any isoform of the said miRNA and all members of the said miRNA family are capable of counteracting expression of the specific gene products.
  • miRNA encompasses any miRNA member.
  • hsa-mir-191* has-miR-15b, hsa-miR-1228*, hsa-miR-181a, hsa-miR-18a*, hsa-miR-107, hsa-miR-299-3p, hsa-miR-342-3p, hsa-miR-652, hsa-miR-191, has-miR-302d, hsa-miR-30e, hsa-miR-744, solexa-2952-306, and solexa-3927-221 are known in the art, their association with heart failure and their effect on heart failure was unknown before the present invention.
  • stimulating the expression of certain of these specific gene products for instance by preventing the expression of the miRNAs, will result in a higher amount of other of these specific gene products, which may also diminish the onset, progression and/or effects of heart failure. This is particularly true for gene products whose expression is regulated by miRNAs that are downregulated during heart failure. These specific gene products are therefore indicated as important mediators of heart failure, by yet unknown mechanisms.
  • RNAs selected from hsa-mir-191*, hsa-miR-15b, hsa-miR-1228*, hsa-mir-181a, hsa-mir-18a*, hsa-mir-107, hsa-mir-299-3p, hsa-mir-342-3p, hsa-mir-652, hsa-mir-191, hsa-mir-302d, hsa-mir-30e, hsa-mir-744, solexa- 2952-306, and solexa-3927-221 are capable of counteracting heart failure, by counteracting the expression of specific gene products.
  • One embodiment therefore provides a method for counteracting, treating, diminishing, delaying and/or preventing heart failure, in a subject, the method comprising:
  • an miRNA selected from the group consisting of hsa-mir-191, hsa-mir-302d, hsa-mir- 3Oe, hsa-mir-744, solexa-2952-306, and solexa-3927-221, or a functional part or derivative thereof, within said subject, and/or
  • said miRNA comprises any member of the said miRNA family, and/or
  • an miRNA selected from the group consisting of from hsa-mir-191*, hsa-miR-15b, hsa-miR-1228*, hsa-mir-181a, hsa-mir-18a*, hsa-mir-107, hsa-mir-299-3p, hsa-mir-342-3p, hsa-mir-652, or a functional part or derivative thereof, within said subject, and/or
  • said miRNA comprises any member of the said miRNA family.
  • said subject has been diagnosed with heart failure. In another embodiment, however, said subject has an increased risk of heart failure, for instance because said subject is already suffering from injury or disease. In an alternative embodiment, a method according to the invention is performed in order to generally prevent heart failure, in an unaffected subject.
  • a subject is for instance diagnosed with heart failure, by determining whether mechanical stiffness is increased, whether normal functions, such as for instance electrical properties of the heart, are decreased, whether ECM proteins are accumulated excessively and/or whether levels of specific gene products are above a certain threshold level.
  • An increased risk of heart failure is often present in a subject when the subject is suffering from an injury or disorder.
  • Methods of the invention are suitable for diagnostic and therapeutic use for heart failure.
  • a method according to the invention is used in order to counteract, treat, diminish, delay and/or prevent cardiac failure.
  • a method for treating and/or preventing heart failure in a subject comprising:
  • said subject has been diagnosed with cardiac failure, or with a risk of cardiac failure.
  • said method is performed in order to generally prevent cardiac failure, in an unaffected subject.
  • the amount of the miRNA is increased by administering the pri-miRNA and/or the pre-miRNA and/or the miRNA, or a functional part or derivative thereof, to said subject.
  • Administration of any of these compounds, or any combination of these compounds results in (increased) counteraction of target mRNA and, thus, counteraction and/or prevention of heart failure.
  • the pri- miRNA is the primary transcript of the miRNA, having a length of several kilobases, which is obtained after transcription of the genomic miRNA sequence by RNA polymerase II.
  • Pre-miRNA is the shorter, 70-100 nucleotide stem- loop structure which is obtained after processing of the pri-miRNA by the ribonuclease Drosha.
  • the sequences of the miRNAs as indicated herein is depicted in Figure 3.
  • a functional part of the pri-miRNA or pre-miRNA or miRNA is defined herein as a nucleic acid sequence with a length of at least 7 nucleotides which is shorter then the pri-miRNA or pre-miRNA or (mature) miRNA, respectively, and which is capable of binding a target mRNA gene (the gene encoding the mRNA to which the miRNA binds) and/or target mRNA and counteracting expression of the protein from the target mRNA or the gene.
  • Said functional part is preferably capable of binding the same 3' UTR region of target mRNA which is capable of being bound by the miRNA.
  • Said functional part preferably comprises a sequence of the seed region of the miRNA.
  • a seed region of the miRNA is present in the 5' region of the naturally occurring miRNA. Said seed region is particularly involved in target recognition.
  • the sequence of the seed region of the miRNA can be found by the skilled artisan without difficulty or inventive skill by performing binding experiments between the miRNA and the mRNA.
  • a functional part of the pri-miRNA or pre- miRNA or miRNA is thus preferably a nucleic acid sequence with a length of at least 7 nucleotides, comprising the seed region sequence. However, slight modifications of said seed region are allowed, as long as the capability of binding a target mRNA gene or the target mRNA is maintained.
  • a functional part of the pri- miRNA or pre-miRNA or miRNA thus also comprises a nucleic acid sequence with a length of at least 7 nucleotides, comprising a sequence which has at least 72%, more preferably at least 80%, more preferably at least 86%, most preferably at least 90% sequence identity with the sequence of the seed region of the miRNAs as indicated herein.
  • a functional derivative of the pri-miRNA or pre-miRNA or miRNA is defined herein as a molecule which comprises a sequence which has 70% or more, but less than 100%, sequence identity with the pri-miRNA or pre- miRNA or miRNA and which has at least one same property in common irrespective of quantitative considerations.
  • Said functional equivalent is capable of binding a target mRNA gene and/or target mRNA and counteracting expression of the protein encoded by the said gene, albeit not necessarily to the same extent as the pri-miRNA or pre-miRNA or miRNA.
  • Such functional equivalent for instance comprises:
  • nucleotides 1-40 % are substituted by one or more other nucleotides, as long as the seed region sequence retains at least 72% sequence identity with the miRNA sequence as indicated in Figure 3;
  • a functional equivalent of the pri-miRNA or pre-miRNA or miRNA has a nucleotide sequence having at least about 75% sequence identity with the pri-miRNA or pre-miRNA or miRNA, preferably at least about 80%, more preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95%.
  • sequence identity the more closely said functional equivalent resembles the pri-miRNA or pre-miRNA or miRNA.
  • a preferred example of a functional equivalent of the pri-miRNA or pre-miRNA or miRNA is a vector comprising at least the seed region of the miRNA, or a vector comprising a sequence which has at least 72%, preferably at least 80%, more preferably at least 86%, most preferably at least 90% sequence identity with the seed region sequence.
  • % sequence identity is defined herein as the percentage of nucleotides in a nucleic acid sequence that is identical with the nucleotides in a nucleic aid sequence of interest, after aligning the sequences and optionally introducing gaps, if necessary, to achieve the maximum percent sequence identity. Methods and computer programs for alignments are well known in the art.
  • nucleic acid sequence and “nucleotides” also encompass non-natural molecules based on and/or derived from nucleic acid sequences, such as for instance artificially modified nucleic acid sequences, peptide nucleic acids, as well as nucleic acid sequences comprising at least one modified nucleotide and/or non-natural nucleotide such as for instance inosine.
  • Methods for introducing polynucleotides into a cell are known in the art. Methods for introducing nucleic acid for instance comprise calcium phosphate transfection, DEAE-Dextran, electroporation or liposome- mediated transfection. Alternatively, direct injection of the polynucleotide is employed.
  • a nucleic acid sequence is introduced into a cell by a vector, preferably a viral vector.
  • Said vector preferably comprises a retroviral, adenoviral, adeno-associated viral (AAV), or lentiviral vector. In one embodiment an AAV9 vector is used.
  • the pri-miRNA or pre-miRNA or miRNA or a functional part or derivative thereof is used which is able to be introduced into a mammalian cell in vivo.
  • Non-limiting examples of methods according to the invention are the coupling of said nucleic acid sequence to cell-penetrating peptides, to microcarriers or to nanocarriers, or the use of liposomes containing said nucleic acid sequence.
  • said inhibitor is targeted to heart muscle cells, for instance by using artificial HDL-like particles bound to said inhibitor, enhancing delivery to the myocardium.
  • heart failure is particularly well counteracted and/or prevented by administering the pri-miRNA or pre-miRNA or miRNA that is downregulated or underexpressed in said subject, or a functional part or derivative thereof, to a subject suffering from, or at risk of suffering from, heart failure.
  • Heart failure is also counteracted and/or prevented by administering a compound capable of increasing or restoring the expression, amount and/or activity of an miRNA that is downregulated or underexpressed in said subject, or by administering a compound capable of increasing interaction of the target mRNA with the miRNA that is downregulated or underexpressed in said subject.
  • the invention therefore further provides pri-miRNA and/or pre- miRNA and/or miRNA that is downregulated or underexpressed in said subject, or a functional part or derivative thereof, or a compound capable of increasing or restoring the expression, amount and/or activity of miRNA that is downregulated or underexpressed in heart failure as indicated herein in a cell, or a compound capable of increasing interaction of the target mRNA with the miRNA that is downregulated or underexpressed in heart failure as indicated herein, for use in counteracting, treating, diminishing, delaying and/or preventing heart failure.
  • the opposite is true for the miRNA that is upregulated or overexpressed in heart failure as indicated herein.
  • the above-mentioned compounds, or any combination thereof, are thus particularly suitable for the preparation of a medicament or prophylactic agent against heart failure.
  • Said prophylactic agent is particularly suitable for subjects with an increased risk of heart failure, as well as for subjects already suffering from heart failure. However, said prophylactic agent is also suitable for generally preventing heart failure, in unaffected subjects.
  • any of the above mentioned compounds, or any combination thereof, to a subject is particularly suitable for counteracting and/or preventing heart failure, in said subject.
  • any of the above mentioned compounds, or any combination thereof is administered to a subject who has been diagnosed with heart failure.
  • any of the above mentioned compounds, or any combination thereof is administered to a subject with an increased risk of heart failure, for instance a subject who is already suffering from injury or disease.
  • said compounds, or any combination thereof are also suitable for generally preventing heart failure, in unaffected subjects.
  • the presence or risk of heart failure is established by determining whether the amount of the pri-miRNA and/or pre-miRNA and/or miRNAs associated with heart failure as identified herein in a sample of a subject is above or below a certain reference value.
  • said reference value represents the amount of pri- miRNA and/or pre-miRNA and/or miRNA selected from the group consisting of miR-191, miR-302d, miR-30e, miR-744, solexa-2952- 306, and solexa-3927-221 in a healthy subject or healthy population. If the amount of the said pri-miRNA and/or pre-miRNA and/or miRNA in a sample of a subject is significantly below the reference value, the expression of the target mRNA is not sufficiently counteracted. As a result, expression of the protein encoded by the target mRNA will be too high and the subject is suffering from, or at risk of suffering from, heart failure. In such case, a therapy according to the present invention is recommended.
  • target mRNA expression (or the translation of the target mRNA into protein) is to severely counteracted.
  • the subject is also diagnosed as suffering from, or at risk of suffering from, heart failure. If the amount of the pri-miRNA and/or pre-miRNA and/or miRNA in a sample of a subject is essentially the same as the reference value, target mRNA expression is sufficiently counteracted. In this case, the subject is not diagnosed as suffering from, or at risk of suffering from, heart failure.
  • a reference value can be used that represents the amount of the pri-miRNA and/or pre-miRNA and/or miRNA in a subject or population suffering from heart failure.
  • a sample with an amount of the pri-miRNA and/or pre-miRNA and/or miRNA which is essentially the same as said reference value indicates (a risk of) heart failure.
  • a sample wherein said value is much smaller or larger indicates health.
  • the invention therefore provides a method for determining whether a subject is suffering from heart failure, or whether a subject has an increased risk of developing heart failure, the method comprising:
  • the amount of the pri-miRNA and/or pre-miRNA and/or miRNA in a sample of a subject is preferably established using a binding compound. At least part of a sample is preferably contacted with such binding compound (optionally after previous processing of the sample), where after unbound components are preferably washed away and bound compounds are preferably visualized and quantified.
  • One embodiment thus provides a method according to the invention for determining whether a subject is suffering from heart failure, or whether a subject has an increased risk of developing heart failure, the method further comprising contacting at least part of said sample with at least one compound capable of specifically binding the pri-miRNA and/or pre-miRNA and/or miRNA.
  • a part is used which contains microRNA so that a suitable test is carried out.
  • the sample is preferably a blood or plasma sample.
  • kit of parts for carrying out a method according to the present invention. Further provided is thus a kit of parts comprising:
  • kits of parts for carrying out a therapy according to the present invention furthermore provides a kit of parts for carrying out a therapy according to the present invention.
  • target mRNA expression is typically counteracted via miRNA.
  • a kit of parts according to the invention comprises:
  • Said pri-miRNA and/or pre-miRNA and/or miRNA indicated herein as downregulated or underexpressed in heart failure, or a functional part or derivative thereof is preferably present in a vector. It is also possible to use a vector comprising a nucleic acid sequence encoding any of the above-mentioned compounds.
  • Said vector preferably comprises a viral vector, most preferably a retroviral, adenoviral, adeno-associated viral or lentiviral vector.
  • an AAV9 vector is used. Further provided is therefore a vector comprising:
  • nucleic acid sequence encoding a compound capable of increasing or restoring the expression, amount and/or activity of the miRNA indicated herein as downregulated or underexpressed in heart failure in a cell, and/or
  • nucleic acid sequence encoding a compound capable of increasing interaction of the target mRNA with the miRNA indicated herein as downregulated or underexpressed in heart failure.
  • said vector comprises: - one or more of miR-191, miR-302d, miR-30e, miR-744, solexa-
  • nucleic acid sequence encoding a compound capable of increasing or restoring the expression, amount and/or activity of one or more of miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221 in a cell, and/or
  • nucleic acid sequence encoding a compound capable of increasing interaction of the target mRNA of one or more of miR-191, miR- 302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221, with miR- 191, miR-302d, miR-30e, miR-744, solexa-2952-306, or solexa-3927-221.
  • a vector according to the invention preferably comprises a retroviral, adenoviral, adeno-associated viral or lentiviral vector.
  • said vector comprises an AAV9 vector.
  • Any of the above mentioned nucleic acid sequences of a vector according to the invention are preferably operably linked to a promoter, so that expression of said nucleic acid will occur after transfection.
  • Said promoter is preferably suitable for expression in a mammalian cell.
  • a vector according to the invention is suitable for expression in a cardiac cell, so that (a risk of) heart failure, is counteracted.
  • said vector preferably comprises a promoter suitable for expression in a cardiac cell.
  • a vector according to the invention comprises a ubiquitous promoter. It is advantageous to use an inducible promoter, so that expression of (at least one) nucleic acid of a vector according to the invention is regulated at will.
  • inducible promoters are cardiac troponin and alpha myosin heavy chain, which are cardiomyocyte specific promoters.
  • a cardiac fibroblast specific promoter may be used.
  • a vector according to the invention is particularly suitable for therapy. Further provided is therefore a use of a vector as defined above for the preparation of a medicament and/or prophylactic agent for counteracting, treating, diminishing, delaying and/or preventing heart failure.
  • a method for counteracting, treating, diminishing, delaying and/or preventing heart failure, in a subject comprising administering a therapeutically amount of a vector according to the invention to the subject.
  • said vector preferably comprises a retroviral, adenoviral, adeno-associated viral or lentiviral vector.
  • an AAV9 vector is used.
  • An isolated or recombinant cell comprising a vector according to the invention is also herewith provided. It is possible to provide cells with the pri-miRNA and/or pre- miRNA and/or miRNA in vitro. Such cells are particularly suitable for research purposes. Moreover, such cells are suitable for therapy.
  • cells overexpressing one or more of miR-191, miR-302d, miR-30e, miR-744, solexa-2952-306, and solexa-3927-221 can be administered to a subject in order to decrease the risk of heart failure.
  • the use of an isolated cell capable of overexpressing, and preferably excreting, one or more of the proteins encoded by target mRNAs of the miRNAs indicated herein as being overexpressed in subjects suffering from heart failure is envisaged.
  • compositions allowing prevention and or treatment of heart failure comprising one or a combination of compounds indicated herein together with a pharmaceutically acceptable carrier, diluent or excipient are also provided herein.
  • a pharmaceutical composition according to the invention may comprise the pri-miRNA and/or pre-miRNA and/or miRNA, or a functional part or derivative thereof of an miRNA of which the downregulation or underexpression as indicated herein is associated with heart failure, and/or
  • a method for counteracting, treating, diminishing, delaying and/or preventing heart failure, in a subject comprising administering a therapeutically amount of a pharmaceutical composition according to the invention to the subject.
  • non-human animal comprising:
  • an exogenous nucleic acid sequence comprising one or more of the pri-miRNA and/or pre-miRNA and/or miRNA, or a functional part or derivative thereof of which the up or downregulation is associated with heart failure as indicated herein, and/or
  • an exogenous nucleic acid sequence encoding a compound capable of increasing or inhibiting the expression, amount and/or activity of miRNA, of which the up- or downregulation is associated with heart failure as indicated herein, or a functional part or derivative thereof, in a cell, and/or
  • Said non-human animal preferably comprises a mammal.
  • said non-human animal comprises a test animal such as a rodent, a rabbit, a goat, a cow, a sheep or a monkey.
  • a non-human animal which has been provided with a vector, an isolated cell, and/or a pharmaceutical composition according to the invention is also provided.
  • a non-human animal according to the invention is especially useful for screening, detection and/or identification of candidate compounds capable of inhibiting or decreasing expression, amount and/or activity of an miRNA that is uregulated in heart failure as indicated herein.
  • Such non-human test animal is also especially useful for screening, detection and/or identification of candidate compounds capable of decreasing interaction of the target mRNA with its corresponding miRNA.
  • a non-human test animal according to the invention is especially useful for screening, detection and/or identification of candidate compounds capable of inducing or enhancing heart failure. If a candidate compound appears to have this property, it is recommended to avoid administration to human subjects.
  • the subject is preferably a mammal, most preferably a human, and the miRNAs as indicated herein refer in preferred embodiments to the homo sapience (hsa) miRNAs.
  • a method for screening, detection and/or identification of candidate compounds capable of counteracting, treating, diminishing, delaying and/or preventing heart failure is provided.
  • candidate compounds are typically screened for their potential capabilities of increasing the expression, amount and/or activity of an miRNA of which the downregulation is associated with heart failure, for their potential capabilities of decreasing the expression, amount and/or activity of an miRNA of which the upregulation is associated with heart failure, or which have capabilities of counteracting the effects of the aberrant protein expression associated with the aberrant miRNA expression as indicated herein. If a candidate compound appears to have this property, it is capable of counteracting or preventing heart failure. Further provided is therefore a method for determining whether a candidate compound is capable of counteracting, treating, diminishing, delaying and/or preventing heart failure, the method comprising:
  • a candidate compound is contacted with a cell according to the present invention wherein expression of the miRNA (preferably which is downregulated in heart failure) is diminished, so that the effects of candidate compounds upon the miRNA expression or activity is more clearly visible. It is, however, also possible to use any cell or non-human animal currently known in the art in a screening method according to the invention. In one embodiment, a non-human animal according to the invention is used.
  • candidate compounds are screened for their capability of increasing interaction of the target mRNA with the miRNAs as indicated herein, or with a functional part or derivative thereof. If a candidate compound appears to have this property in relation to the miRNA of which the downregulation is associated with heart disease, it is capable of counteracting or preventing heart failure. Further provided is therefore a method for determining whether a candidate compound is capable of counteracting, treating, diminishing, delaying and/or preventing heart failure, the method comprising:
  • compositions can comprise polypeptides, polynucleotides or small molecules of the claimed invention, collectively called pharmaceutical compounds herein.
  • the pharmaceutical compositions will comprise a therapeutically effective amount of either a biomarker protein, a polynucleotides or small molecule as described herein.
  • therapeutically effective amount refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect.
  • the effect can be detected by, for example, chemical markers or antigen levels.
  • Therapeutic effects also include reduction in physical symptoms.
  • the precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgment of the clinician.
  • an effective dose will be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the polynucleotide or polypeptide compositions in the individual to which it is administered.
  • a pharmaceutical composition can also contain a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier refers to a carrier for administration of a therapeutic agent, such as a polypeptide, polynucleotide, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
  • Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
  • Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
  • mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like
  • organic acids such as acetates, propionates, malonates, benzoates, and the like.
  • Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
  • the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
  • Liposomes are included within the definition of a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions of the invention can be (1) administered directly to the subject; (2) delivered ex vivo, to cells derived from the subject; or (3) delivered in vitro for expression of recombinant proteins.
  • Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue.
  • the compositions can also be administered into the nervous system.
  • Other modes of administration include topical, oral, suppositories, and transdermal applications, needles, and particle guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • cells useful in ex vivo applications include, for example, stem cells, particularly hematopoietic, lymph cells, macrophages, dendritic cells, or tumor cells.
  • nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.
  • Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues is also used.
  • Receptor-mediated DNA delivery techniques are described in, for example, Findeis et at., Trends in Biotechnol. (1993) 11:202-205; Wu et al., J. Biol. Chem. (1994) 269:542-46.
  • compositions containing polynucleotides are preferably administered in a range of about 100 ng to about 200 mg of polynucleotides for local administration in a gene therapy protocol.
  • Concentration ranges of about 500 ng to about 50 mg, about 1 ⁇ g to about 2 mg, about 5 ⁇ g to about 500 ⁇ g, and about 20 ⁇ g to about 100 ⁇ g of polynucleotides can also be used during a gene therapy protocol.
  • Factors such as method of action and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the polynucleotides.
  • MiRNA expression profiles was performed using the Illumina human miRNA Expression Profiling Panel (User card for bead chip cat#MI-501-1001, part#l 1297760 RevA). Normalization was performed using Genespring software.
  • a total of 9 miRNAs were found to be significantly upregulated in the blood of heart failure patients, and 6 miRNA were down-regulated. (See table 1, and figure 1 and 2).
  • differentially regulated miRNAs may be used as biomarkers for the detection of heart failure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur un procédé pour traiter et prévenir une insuffisance cardiaque chez un sujet. Le procédé comporte l'étape consistant à diminuer, à l'intérieur dudit sujet, l'expression, la quantité et/ou l'activité d'au moins un ARNmi, ou à diminuer, à l'intérieur dudit sujet, l'interaction d'au moins un ARNmi avec son ARNm cible, ou à augmenter à l'intérieur dudit sujet l'expression, la quantité et/ou l'activité de l'ARNm cible d'au moins un ARNmi, ledit ou lesdits ARNmi étant choisis dans le groupe constitué par miR-191*, miR-15b, miR-1228*, miR-181a, miR-18a*, miR-107, miR-299-3p, mi R-342-3p et miR-652.
PCT/NL2009/050237 2009-04-29 2009-04-29 Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque WO2010126355A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PCT/NL2009/050237 WO2010126355A1 (fr) 2009-04-29 2009-04-29 Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque
PCT/NL2010/050251 WO2010126370A2 (fr) 2009-04-29 2010-04-29 Moyens et procédés pour contrebalancer, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
US13/263,976 US20120115929A1 (en) 2009-04-29 2010-04-29 Means And Methods For Counteracting, Preventing And/Or Determining Heart Failure, Or A Risk Of Heart Failure
JP2012508418A JP5871791B2 (ja) 2009-04-29 2010-04-29 心不全または心不全の危険性を中和、予防および／または決定する手段および方法
PL10769995T PL2425016T3 (pl) 2009-04-29 2010-04-29 Środki i sposoby przeciwdziałania, zapobiegania i/lub określania niewydolności serca lub ryzyka niewydolności serca
AU2010242163A AU2010242163B2 (en) 2009-04-29 2010-04-29 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
EP10769995.1A EP2425016B1 (fr) 2009-04-29 2010-04-29 Moyens et procédés pour contrebalancer, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
CA2758928A CA2758928A1 (fr) 2009-04-29 2010-04-29 Moyens et procedes pour contrebalancer, prevenir et/ou determiner une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
CN201080018687.1A CN102421917B (zh) 2009-04-29 2010-04-29 对抗、预防和/或测定心力衰竭或心力衰竭的风险的工具和方法
CN201410314395.2A CN104087662A (zh) 2009-04-29 2010-04-29 对抗、预防和/或测定心力衰竭或心力衰竭的风险的工具和方法
KR1020117028404A KR101758667B1 (ko) 2009-04-29 2010-04-29 심부전 또는 심부전 위험성을 방지, 예방 및/또는 측정하기 위한 수단 및 방법
EP15158646.8A EP2907879A3 (fr) 2009-04-29 2010-04-29 Moyens et procédés pour combattre, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
SG2011079399A SG175821A1 (en) 2009-04-29 2010-04-29 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
DK10769995.1T DK2425016T3 (en) 2009-04-29 2010-04-29 MEANS AND METHODS TO REMEDY THE, PREVENT AND / OR diagnose heart failure or EN risk of cardiac failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2009/050237 WO2010126355A1 (fr) 2009-04-29 2009-04-29 Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque

Publications (1)

Publication Number Publication Date
WO2010126355A1 true WO2010126355A1 (fr) 2010-11-04

Family

ID=41531922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2009/050237 WO2010126355A1 (fr) 2009-04-29 2009-04-29 Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque

Country Status (1)

Country Link
WO (1) WO2010126355A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525144A (ja) * 2009-04-29 2012-10-22 アカデミス・メディス・セントルム・ベイ・デ・ウニフェルジテイト・ファン・アムステルダム 心不全または心不全の危険性を中和、予防および／または決定する手段および方法
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
RU2662975C1 (ru) * 2011-10-21 2018-07-31 Оспиталь Клиник Де Барселона Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака
CN111705125A (zh) * 2020-07-30 2020-09-25 武汉舒特尔生物科技有限公司 miR-299-5p作为肺动脉高血压无创诊断标志中及检测试剂盒
US11236332B2 (en) * 2011-12-23 2022-02-01 King's College London MicroRNAs for cardiac regeneration through induction of cardiac myocyte proliferation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (fr) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
WO2009012468A2 (fr) * 2007-07-18 2009-01-22 The Regents Of The University Colorado Expression différentielle de microarn de cœurs humains non insuffisants contre des cœurs humains insuffisants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (fr) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
WO2009012468A2 (fr) * 2007-07-18 2009-01-22 The Regents Of The University Colorado Expression différentielle de microarn de cœurs humains non insuffisants contre des cœurs humains insuffisants

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525144A (ja) * 2009-04-29 2012-10-22 アカデミス・メディス・セントルム・ベイ・デ・ウニフェルジテイト・ファン・アムステルダム 心不全または心不全の危険性を中和、予防および／または決定する手段および方法
RU2662975C1 (ru) * 2011-10-21 2018-07-31 Оспиталь Клиник Де Барселона Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака
US11236332B2 (en) * 2011-12-23 2022-02-01 King's College London MicroRNAs for cardiac regeneration through induction of cardiac myocyte proliferation
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN111705125A (zh) * 2020-07-30 2020-09-25 武汉舒特尔生物科技有限公司 miR-299-5p作为肺动脉高血压无创诊断标志中及检测试剂盒

Similar Documents

Publication Publication Date Title
EP2425016B1 (fr) Moyens et procédés pour contrebalancer, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
CA2977624C (fr) Composition pharmaceutique pour le traitement du cancer comprenant un micro-arn en tant que principe actif
US20190276892A1 (en) Micrornas in neurodegenerative disorders
US20180057818A1 (en) Mirna modulators of thermogenesis
EP2610342B1 (fr) Expression du miRNA dans des microvésicules sanguines périphériques humaines et leurs utilisations
CN102892897B (zh) 用于肺癌的微rna表达谱分析的组合物和方法
DK2684955T3 (en) Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
DK3134526T3 (en) LNC RNAs for therapy and diagnosis of cardiac hypertrophy
CN106687602A (zh) 用于诊断和治疗骨折和骨病的组合物及方法
EP2298359A1 (fr) Acide nucléique capable de réguler la dégranulation d'un mastocyte
KR20080080177A (ko) 마이크로 ｒｎａ를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 ｒｎａ 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트
WO2011076143A1 (fr) Compositions et méthodes de profilage du cancer du poumon par expression de microarn
WO2009023525A2 (fr) Procédés de modulation de la différenciation des cellules souches mésenchymateuses
EP2314678B1 (fr) Micro-arn associé à l'arthrite rhumatoïde
CN108699603A (zh) 用于诊断和治疗骨折和骨病的组合物和方法
WO2010126355A1 (fr) Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque
WO2013134403A1 (fr) Procédé de traitement de maladies neurodégénératives avec des régulateurs de micro-arn
US20140194491A1 (en) Modulation of microrna-138 for the treatment of bone loss
US9127273B2 (en) UNC-45A splice variants based cancer diagnostics and therapeutics
Islam et al. MicroRNA-455-3P as a peripheral biomarker and Therapeutic Target for Mild Cognitive Impairment and Alzheimer’s disease
Alissa et al. From Molecules to Heart Regeneration: Understanding the Complex and Profound Role of Non-Coding RNAs in Stimulating Cardiomyocyte Proliferation for Cardiac Repair
CN110184271A (zh) 一种mRNA-like ncRNA、抑制其表达的反义RNA及两者的应用
FI20195871A1 (fi) Synteettiset pienet rna:t

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09788181

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09788181

Country of ref document: EP

Kind code of ref document: A1